Key result
Bosutinib use in chronic myeloid leukemia is associated with cardiovascular toxicity, though the exact mechanisms of these complications remain not fully understood.
Why the study?
New therapies for CML have been linked to cardiovascular toxicity, including complications associated with bosutinib whose mechanisms are not fully understood.
Does bosutinib cause cardiovascular toxicity in patients with chronic myeloid leukemia?
Does bosutinib cause cardiovascular toxicity in patients with chronic myeloid leukemia?
This review highlights the importance of recognizing and understanding cardiovascular toxicity associated with bosutinib therapy in patients with chronic myeloid leukemia.
Chronic myeloid leukemia (CML) is the fifth most common type of hemoblastosis. The prognosis for CML patients has improved dramatically with the advent of targeted therapy, and their life expectancy is now comparable to that of the general population. However, despite the high rates of overall survival and molecular response achieved with first-generation drug imatinib, patients often develop resistance to therapy. This has led to the search for new molecules for treating CML. However, the use of new drugs has been associated with cardiovascular toxicity, including complications with the use of bosutinib, whose mechanism of occurrence is not fully understood. This literature review is based on reliable sources and focuses on the use of bosutinib and its effect on the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Sabina G. Cherenova (2023) conducted a review in Chronic myeloid leukemia (CML). Bosutinib was evaluated. Bosutinib use in chronic myeloid leukemia is associated with cardiovascular toxicity, though the exact mechanisms of these complications remain not fully understood.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: